항VEGF 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Anti-VEGF Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 6,876,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,043,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,695,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 이번에 항VEGF 시장에 관한 종합 보고서를 발표했습니다. 촉진요인·동향·기회·과제를 포함한 중요 시장 역학을 철저히 평가하고, 시장 구조에 관한 상세 인사이트을 제공하고 있습니다.

주요 인사이트

• 항VEGF 시장 규모(2024년) : 238억 달러
• 예측 시장 금액(2033년) : 351억 달러
• 세계 시장 성장률(CAGR 2024-2033년) : 4.4%

항VEGF 시장 - 조사 범위 :

항VEGF 요법은 노화성 황반변성(AMD), 당뇨망막병증, 일부 암을 포함한 다양한 질환의 치료에 중요한 역할을 하고 있습니다. 이들 치료제는 혈관내피성장인자(VEGF)를 표적으로 하여 혈관신생을 억제하고 질병의 진행을 효과적으로 관리합니다. 항VEGF 시장은 주로 병원, 클리닉, 안과 센터 및 전문 치료 시설을 대상으로 하며, 유리체강내 주사 및 경구용 약물 등 다양한 치료 옵션을 제공합니다.

시장 성장 촉진요인:

세계 AMD 및 당뇨망막병증의 유병률 증가, 약물의 효과와 환자 예후를 개선하는 바이오테크놀러지의 발전, 항VEGF 치료의 조기 개입의 이점에 대한 의료진들의 인식이 높아짐에 따라 시장 성장에 대한 기대감이 높아지고 있습니다. 약물전달 시스템의 기술 혁신과 원격의료 서비스의 확대는 치료 접근성과 환자 순응도를 향상시켜 시장 성장을 더욱 촉진할 것입니다.

시장 성장 억제요인 :

유망한 성장 전망에도 불구하고, 항VEGF 시장은 높은 치료 비용, 의약품 승인 및 시장 진입과 관련된 복잡한 규제, 장기 치료에 따른 잠재적 부작용과 관련된 도전 과제에 직면해 있습니다. 또한 일부 지역에서는 항VEGF 치료제에 대한 제한된 보험 적용 범위도 시장 확대에 걸림돌로 작용하고 있으며, 특히 의료비 지출을 효율적으로 관리하려는 신흥 국가에서는 더욱 그러합니다.

시장 기회 :

항VEGF 시장은 새로운 제형, 맞춤형 의료 접근법, 여러 질병 경로를 표적으로 하는 병용요법에 초점을 맞춘 연구개발이 진행 중이며, 이는 큰 성장 기회를 제공합니다. 제약사, 연구기관, 의료기관의 전략적 제휴는 기술 혁신을 가속화하고 안과 및 종양학 분야의 미충족 의료 수요를 충족시키기 위해 필수적입니다.

이 보고서에서 다룬 주요 질문

• 항VEGF 시장의 세계 성장을 촉진하는 주요 요인은 무엇인가?
• 다른 헬스케어 환경에서 항VEGF의 채택을 촉진하고 있는 치료 용도와 환자층은 무엇인가?
• 기술의 진보는 항VEGF 시장의 경쟁 구도를 어떻게 바꾸고 있는가?
• 항VEGF 시장에 기여하고 있는 주요 기업은 어디이며, 시장의 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계의 항VEGF 시장 새로운 동향과 전망은?

목차

제1장 개요

제2장 시장 개요

• 시장 범위/분류
• 시장의 정의/범위/제한
• 포함 사항·제외 사항

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 주요 성공 요인

• 규제 상황
• 파이프라인 평가
• 제품의 채택과 사용 상황 분석
• 기업이 채택하는 주요 마케팅 및 프로모션 전략
• PESTLE 분석
• Porter의 산업 분석
• 밸류체인 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19로 영향 분석
  • 매출 : 약제 유형별
  • 매출 : 유형별
  • 매출 : 질환 적응증별
  • 매출 : 유통 채널별
  • 국가별
• 2024년 시장 시나리오

제7장 세계 시장의 수요(금액 또는 규모, 10억 달러) 분석

• 과거 시장 금액(10억 달러) 분석, 2019-2023년
• 현재 및 향후 시장 금액(10억 달러) 예측, 2024-2033년
  • 전년대비 성장 동향 분석
  • 절대액 기회 분석

제8장 세계 시장 분석 : 약제 유형별

• 서론/주요 조사 결과
• 과거 시장 규모(10억 달러) 분석 : 약제 유형별, 2019-2023년
• 현재 및 향후 시장 규모(10억 달러) 분석과 예측 : 약제 유형별, 2024-2033년
  • 소분자
  • 생물학적 제제
• 시장의 매력 분석 : 약제 유형별

제9장 세계 시장 분석 : 유형별

• 서론/주요 조사 결과
• 과거 시장 규모(10억 달러) 분석 : 유형별, 2019-2023년
• 현재 및 향후 시장 규모(10억 달러) 분석과 예측 : 유형별, 2024-2033년
  • VEGF A 저해제
  • VEGF B 저해제
  • VEGF C 저해제
  • 태반 성장인자 저해제
• 시장의 매력 분석 : 유형별

제10장 세계 시장 분석 : 질환 적응증별

• 서론/주요 조사 결과
• 과거 시장 규모(10억 달러) 분석 : 질환 적응증별, 2019-2023년
• 현재 및 향후 시장 규모(10억 달러) 분석과 예측 : 질환 적응증별, 2024-2033년
  • 종양학
  • 혈액 질환
  • 안과 질환
• 시장의 매력 분석 : 질환 적응증별

제11장 세계 시장 분석 : 유통 채널별

• 서론/주요 조사 결과
• 과거 시장 규모(10억 달러) 분석 : 유통 채널별, 2019-2023년
• 현재 및 향후 시장 규모(10억 달러) 분석과 예측 : 유통 채널별, 2024-2033년
  • 병원
  • 전문 클리닉
  • 암연구 센터
  • 통신 판매 약국
• 시장의 매력 분석 : 유통 채널별

제12장 세계 시장 분석 : 지역별

• 서론
• 과거 시장 규모(10억 달러) 분석 : 지역별, 2019-2023년
• 현재 및 향후 시장 규모(10억 달러) 분석과 예측 : 지역별, 2024-2033년
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카(MEA)
• 시장의 매력 분석 : 지역별

제13장 북미 시장 분석

제14장 라틴아메리카 시장 분석

제15장 유럽 시장 분석

제16장 동아시아 시장 분석

제17장 남아시아 시장 분석

제18장 오세아니아 시장

제19장 중동 및 아프리카(MEA) 시장 분석

제20장 시장 구조 분석

• 시장 분석 : 기업 계층별
• 주요 기업의 시장 점유율 분석
• 시장 집중
• 시장 입지 분석

제21장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁 상세 정보
  • Pfizer Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi SA
  • Exelixis Inc.
  • Eisai Co. Ltd.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Amneal Pharmaceuticals Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Sino Biopharma
  • HUTCHMED

제22장 사용되는 전제 조건과 두자어

제23장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the Anti-VEGF Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Anti-VEGF Market Size (2024E): USD 23.8 Billion
• Projected Market Value (2033F): USD 35.1 Billion
• Global Market Growth Rate (CAGR 2024 to 2033): 4.4%

Anti-VEGF Market - Report Scope:

Anti-VEGF therapies play a critical role in the treatment of various medical conditions, including age-related macular degeneration (AMD), diabetic retinopathy, and certain types of cancers. These therapies target vascular endothelial growth factor (VEGF) to inhibit angiogenesis and manage disease progression effectively. The Anti-VEGF Market caters primarily to hospitals, clinics, ophthalmology centers, and specialized treatment facilities, offering a range of treatment options, including intravitreal injections and oral medications.

Market Growth Drivers:

The global Anti-VEGF Market is driven by several key factors, including increasing prevalence of AMD and diabetic retinopathy globally, advancements in biotechnology enhancing drug efficacy and patient outcomes, and growing awareness among healthcare providers about the benefits of early intervention with Anti-VEGF therapies. Technological innovations in drug delivery systems and the expansion of telemedicine services further bolster market growth by improving treatment accessibility and patient compliance.

Market Restraints:

Despite promising growth prospects, the Anti-VEGF Market faces challenges related to high treatment costs, regulatory complexities governing drug approvals and market entry, and potential adverse effects associated with long-term therapy. Limited reimbursement coverage for Anti-VEGF treatments in certain regions also poses barriers to market expansion, particularly in emerging economies striving to manage healthcare expenditures effectively.

Market Opportunities:

The Anti-VEGF Market presents significant growth opportunities driven by ongoing research and development initiatives focused on novel drug formulations, personalized medicine approaches, and combination therapies targeting multiple disease pathways. Strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers are essential to accelerate innovation and address unmet medical needs in ophthalmology and oncology.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Anti-VEGF Market globally?
• Which therapeutic applications and patient populations are driving Anti-VEGF adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the Anti-VEGF Market?
• Who are the key players contributing to the Anti-VEGF Market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global Anti-VEGF Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Anti-VEGF Market, including Roche Holding AG, Novartis AG, and Regeneron Pharmaceuticals, Inc., focus on innovation, strategic alliances, and regulatory compliance to gain a competitive edge. These companies invest significantly in clinical trials, regulatory submissions, and post-marketing surveillance to ensure product safety and efficacy. Collaborations with ophthalmologists, oncologists, and patient advocacy groups facilitate market access and promote therapeutic advancements in Anti-VEGF therapy.

Key Companies Profiled:

• Pfizer Inc.
• Novartis AG
• Sanofi SA
• Bayer Healthcare LLC
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Eli Lilly and Company
• Eisai Co., Ltd.
• Sino Pharma
• Amneal Pharmaceuticals Inc.
• Exelixis, Inc.
• HUTCHMED

Key Segments of Anti-VEGF Industry Research

By Drug:

• Small Molecules
• Biologics

By Type:

• VEGF-A Inhibitors
• VEGF-B Inhibitors
• VEGF-C Inhibitors
• Placenta Growth Factor Inhibitors

By Disease Indication:

• Oncology
• Hematology Disorders
• Ophthalmology Disorders

By Distribution Channel:

• Hospitals
• Specialty Clinics
• Mail Order Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage/Taxonomy
• 2.2. Market Definition/Scope/Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Regulatory Landscape
• 4.2. Pipeline Assessment
• 4.3. Product Adoption and Usage Analysis
• 4.4. Key Marketing & Promotional Strategies Adopted by Companies
• 4.5. PESTLE Analysis
• 4.6. Porters Analysis
• 4.7. Value Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Spending Outlook
  • 5.1.3. Global Oncology Therapeutic Medicines Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Increase in R&D Funding and Grants
  • 5.2.2. Rising Research Activities for Rare Disease Indications
  • 5.2.3. High Demand for Biologics
  • 5.2.4. Surge in Research Collaborations for Development of Drugs
  • 5.2.5. High Prevalence of Cancer
  • 5.2.6. New Product Launch
  • 5.2.7. Regulatory Approvals
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. Revenue By Drug Types
  • 6.1.2. Revenue By Types
  • 6.1.3. Revenue By Disease Indication
  • 6.1.4. Revenue By Distribution Channel
  • 6.1.5. Revenue By Country
• 6.2. 2024 Market Scenario

7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Types

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis, By Drug Types, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Types, 2024-2033
  • 8.3.1. Small Molecules
    • 8.3.1.1. Pazopanib
    • 8.3.1.2. Sunitinib
    • 8.3.1.3. Regorafenib
    • 8.3.1.4. Cabozantinib
    • 8.3.1.5. Lenvatinib
    • 8.3.1.6. Ponatinib
    • 8.3.1.7. Cabozantinib
    • 8.3.1.8. Axitinib
    • 8.3.1.9. Tivozanib
    • 8.3.1.10. Vandetanib
    • 8.3.1.11. Sorafenib
    • 8.3.1.12. Anlotinib
    • 8.3.1.13. Apatinib
    • 8.3.1.14. Fruquintinib
    • 8.3.1.15. Surufatinib
  • 8.3.2. Biologics
    • 8.3.2.1. Bevacizumab
    • 8.3.2.2. Ziv-Aflibercept
    • 8.3.2.3. Ramucirumab
    • 8.3.2.4. Ranibizumab
• 8.4. Market Attractiveness Analysis By Drug Types

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Types

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis, By Types, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Types, 2024-2033
  • 9.3.1. VEGF A Inhibitors
  • 9.3.2. VEGF B Inhibitors
  • 9.3.3. VEGF C Inhibitors
  • 9.3.4. Placenta Growth Factor Inhibitors
• 9.4. Market Attractiveness Analysis By Types

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Disease Indication

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Disease Indication, 2024-2033
  • 10.3.1. Oncology
    • 10.3.1.1. Cervical Cancer
    • 10.3.1.2. Non-Small Cell Lung Cancer
    • 10.3.1.3. Renal Cell Carcinoma
    • 10.3.1.4. Soft Tissue Sarcoma
    • 10.3.1.5. Colorectal Cancer
    • 10.3.1.6. Liver Cancer
    • 10.3.1.7. Others
  • 10.3.2. Hematology Disorders
  • 10.3.3. Ophthalmology Disorders
    • 10.3.3.1. Wet Age-Related Macular Degeneration (AMD)
    • 10.3.3.2. Diabetic Retinopathy
    • 10.3.3.3. Others
• 10.4. Market Attractiveness Analysis By Disease Indication

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
  • 11.3.1. Hospitals
  • 11.3.2. Specialty Clinics
  • 11.3.3. Cancer Research Centers
  • 11.3.4. Mail Order Pharmacies
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. East Asia
  • 12.3.5. South Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Drug Types
  • 13.3.3. By Types
  • 13.3.4. By Disease Indication
  • 13.3.5. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug Types
  • 13.4.3. By Types
  • 13.4.4. By Disease Indication
  • 13.4.5. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. U.S. Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Drug Types
      • 13.8.1.2.2. By Types
      • 13.8.1.2.3. By Disease Indication
      • 13.8.1.2.4. By Distribution Channel
  • 13.8.2. Canada Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Drug Types
      • 13.8.2.2.2. By Types
      • 13.8.2.2.3. By Disease Indication
      • 13.8.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. Mexico
    • 14.3.1.2. Brazil
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Drug Types
  • 14.3.3. By Types
  • 14.3.4. By Disease Indication
  • 14.3.5. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug Types
  • 14.4.3. By Types
  • 14.4.4. By Disease Indication
  • 14.4.5. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Mexico Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Drug Types
      • 14.8.1.2.2. By Types
      • 14.8.1.2.3. By Disease Indication
      • 14.8.1.2.4. By Distribution Channel
  • 14.8.2. Brazil Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Drug Types
      • 14.8.2.2.2. By Types
      • 14.8.2.2.3. By Disease Indication
      • 14.8.2.2.4. By Distribution Channel
  • 14.8.3. Argentina Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Drug Types
      • 14.8.3.2.2. By Types
      • 14.8.3.2.3. By Disease Indication
      • 14.8.3.2.4. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. Italy
    • 15.3.1.3. France
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. BENELUX
    • 15.3.1.7. Nordic Countries
    • 15.3.1.8. Russia
    • 15.3.1.9. Rest of Europe
  • 15.3.2. By Drug Types
  • 15.3.3. By Types
  • 15.3.4. By Disease Indication
  • 15.3.5. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug Types
  • 15.4.3. By Types
  • 15.4.4. By Disease Indication
  • 15.4.5. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Drug Types
      • 15.8.1.2.2. By Types
      • 15.8.1.2.3. By Disease Indication
      • 15.8.1.2.4. By Distribution Channel
  • 15.8.2. Italy Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Drug Types
      • 15.8.2.2.2. By Types
      • 15.8.2.2.3. By Disease Indication
      • 15.8.2.2.4. By Distribution Channel
  • 15.8.3. France Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Drug Types
      • 15.8.3.2.2. By Types
      • 15.8.3.2.3. By Disease Indication
      • 15.8.3.2.4. By Distribution Channel
  • 15.8.4. U.K. Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Drug Types
      • 15.8.4.2.2. By Types
      • 15.8.4.2.3. By Disease Indication
      • 15.8.4.2.4. By Distribution Channel
  • 15.8.5. Spain Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Drug Types
      • 15.8.5.2.2. By Types
      • 15.8.5.2.3. By Disease Indication
      • 15.8.5.2.4. By Distribution Channel
  • 15.8.6. BENELUX Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Drug Types
      • 15.8.6.2.2. By Types
      • 15.8.6.2.3. By Disease Indication
      • 15.8.6.2.4. By Distribution Channel
  • 15.8.7. Nordic Countries Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Drug Types
      • 15.8.7.2.2. By Types
      • 15.8.7.2.3. By Disease Indication
      • 15.8.7.2.4. By Distribution Channel
  • 15.8.8. Russia Market Analysis
    • 15.8.8.1. Introduction
    • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.8.2.1. By Drug Types
      • 15.8.8.2.2. By Types
      • 15.8.8.2.3. By Disease Indication
      • 15.8.8.2.4. By Distribution Channel

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. China
    • 16.3.1.2. Japan
    • 16.3.1.3. South Korea
  • 16.3.2. By Drug Types
  • 16.3.3. By Types
  • 16.3.4. By Disease Indication
  • 16.3.5. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug Types
  • 16.4.3. By Types
  • 16.4.4. By Disease Indication
  • 16.4.5. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. China Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Drug Types
      • 16.8.1.2.2. By Types
      • 16.8.1.2.3. By Disease Indication
      • 16.8.1.2.4. By Distribution Channel
  • 16.8.2. Japan Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Drug Types
      • 16.8.2.2.2. By Types
      • 16.8.2.2.3. By Disease Indication
      • 16.8.2.2.4. By Distribution Channel
  • 16.8.3. South Korea Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Drug Types
      • 16.8.3.2.2. By Types
      • 16.8.3.2.3. By Disease Indication
      • 16.8.3.2.4. By Distribution Channel

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. India
    • 17.3.1.2. Indonesia
    • 17.3.1.3. Malaysia
    • 17.3.1.4. Thailand
    • 17.3.1.5. Rest of South Asia
  • 17.3.2. By Drug Types
  • 17.3.3. By Types
  • 17.3.4. By Disease Indication
  • 17.3.5. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug Types
  • 17.4.3. By Types
  • 17.4.4. By Disease Indication
  • 17.4.5. By Distribution Channel
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. India Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Drug Types
      • 17.8.1.2.2. By Types
      • 17.8.1.2.3. By Disease Indication
      • 17.8.1.2.4. By Distribution Channel
  • 17.8.2. Indonesia Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Drug Types
      • 17.8.2.2.2. By Types
      • 17.8.2.2.3. By Disease Indication
      • 17.8.2.2.4. By Distribution Channel
  • 17.8.3. Malaysia Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Drug Types
      • 17.8.3.2.2. By Types
      • 17.8.3.2.3. By Disease Indication
      • 17.8.3.2.4. By Distribution Channel
  • 17.8.4. Thailand Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.4.2.1. By Drug Types
      • 17.8.4.2.2. By Types
      • 17.8.4.2.3. By Disease Indication
      • 17.8.4.2.4. By Distribution Channel

18. Oceania Market 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Drug Types
  • 18.3.3. By Types
  • 18.3.4. By Disease Indication
  • 18.3.5. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug Types
  • 18.4.3. By Types
  • 18.4.4. By Disease Indication
  • 18.4.5. By Distribution Channel
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Drug Types
      • 18.8.1.2.2. By Types
      • 18.8.1.2.3. By Disease Indication
      • 18.8.1.2.4. By Distribution Channel
  • 18.8.2. New Zealand Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Drug Types
      • 18.8.2.2.2. By Types
      • 18.8.2.2.3. By Disease Indication
      • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. South Africa
    • 19.3.1.4. North Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Drug Types
  • 19.3.3. By Types
  • 19.3.4. By Disease Indication
  • 19.3.5. By Distribution Channel
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Drug Types
  • 19.4.3. By Types
  • 19.4.4. By Disease Indication
  • 19.4.5. By Distribution Channel
• 19.5. Market Trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Drug Types
      • 19.8.1.2.2. By Types
      • 19.8.1.2.3. By Disease Indication
      • 19.8.1.2.4. By Distribution Channel
  • 19.8.2. Turkey Anti-VEGF Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Drug Types
      • 19.8.2.2.2. By Types
      • 19.8.2.2.3. By Disease Indication
      • 19.8.2.2.4. By Distribution Channel
  • 19.8.3. South Africa Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Drug Types
      • 19.8.3.2.2. By Types
      • 19.8.3.2.3. By Disease Indication
      • 19.8.3.2.4. By Distribution Channel
  • 19.8.4. North Africa Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Drug Types
      • 19.8.4.2.2. By Types
      • 19.8.4.2.3. By Disease Indication
      • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Concentration
• 20.4. Market Presence Analysis
  • 20.4.1. Regional Footprint Analysis
  • 20.4.2. Channel Footprint Analysis

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. Pfizer Inc.
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Sales Footprint
    • 21.3.1.4. Key Financial
    • 21.3.1.5. Key Developments
    • 21.3.1.6. SWOT Analysis
    • 21.3.1.7. Strategy Overview
      • 21.3.1.7.1. Marketing Strategies
      • 21.3.1.7.2. Channel Strategies
  • 21.3.2. Bayer AG
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Sales Footprint
    • 21.3.2.4. Key Financial
    • 21.3.2.5. Key Developments
    • 21.3.2.6. SWOT Analysis
    • 21.3.2.7. Strategy Overview
      • 21.3.2.7.1. Marketing Strategies
      • 21.3.2.7.2. Channel Strategies
  • 21.3.3. Novartis AG
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Sales Footprint
    • 21.3.3.4. Key Financial
    • 21.3.3.5. Key Developments
    • 21.3.3.6. SWOT Analysis
    • 21.3.3.7. Strategy Overview
      • 21.3.3.7.1. Marketing Strategies
      • 21.3.3.7.2. Channel Strategies
  • 21.3.4. Sanofi SA
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Sales Footprint
    • 21.3.4.4. Key Financial
    • 21.3.4.5. Key Developments
    • 21.3.4.6. SWOT Analysis
    • 21.3.4.7. Strategy Overview
      • 21.3.4.7.1. Marketing Strategies
      • 21.3.4.7.2. Channel Strategies
  • 21.3.5. Exelixis Inc.
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Sales Footprint
    • 21.3.5.4. Key Financial
    • 21.3.5.5. Key Developments
    • 21.3.5.6. SWOT Analysis
    • 21.3.5.7. Strategy Overview
      • 21.3.5.7.1. Marketing Strategies
      • 21.3.5.7.2. Channel Strategies
  • 21.3.6. Eisai Co. Ltd.
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Sales Footprint
    • 21.3.6.4. Key Financial
    • 21.3.6.5. Key Developments
    • 21.3.6.6. SWOT Analysis
    • 21.3.6.7. Strategy Overview
      • 21.3.6.7.1. Marketing Strategies
      • 21.3.6.7.2. Channel Strategies
  • 21.3.7. Amgen Inc.
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Sales Footprint
    • 21.3.7.4. Key Financial
    • 21.3.7.5. Key Developments
    • 21.3.7.6. SWOT Analysis
    • 21.3.7.7. Strategy Overview
      • 21.3.7.7.1. Marketing Strategies
      • 21.3.7.7.2. Channel Strategies
  • 21.3.8. F. Hoffmann-La Roche Ltd.
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Sales Footprint
    • 21.3.8.4. Key Financial
    • 21.3.8.5. Key Developments
    • 21.3.8.6. SWOT Analysis
    • 21.3.8.7. Strategy Overview
      • 21.3.8.7.1. Marketing Strategies
      • 21.3.8.7.2. Channel Strategies
  • 21.3.9. Eli Lilly and Company
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Sales Footprint
    • 21.3.9.4. Key Financial
    • 21.3.9.5. Key Developments
    • 21.3.9.6. SWOT Analysis
    • 21.3.9.7. Strategy Overview
      • 21.3.9.7.1. Marketing Strategies
      • 21.3.9.7.2. Channel Strategies
  • 21.3.10. Amneal Pharmaceuticals Inc.
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Sales Footprint
    • 21.3.10.4. Key Financial
    • 21.3.10.5. Key Developments
    • 21.3.10.6. SWOT Analysis
    • 21.3.10.7. Strategy Overview
      • 21.3.10.7.1. Marketing Strategies
      • 21.3.10.7.2. Channel Strategies
  • 21.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
    • 21.3.11.1. Overview
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Sales Footprint
    • 21.3.11.4. Key Financial
    • 21.3.11.5. Key Developments
    • 21.3.11.6. SWOT Analysis
    • 21.3.11.7. Strategy Overview
      • 21.3.11.7.1. Marketing Strategies
      • 21.3.11.7.2. Channel Strategies
  • 21.3.12. Takeda Pharmaceutical Co. Ltd.
    • 21.3.12.1. Overview
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Sales Footprint
    • 21.3.12.4. Key Financial
    • 21.3.12.5. Key Developments
    • 21.3.12.6. SWOT Analysis
    • 21.3.12.7. Strategy Overview
      • 21.3.12.7.1. Marketing Strategies
      • 21.3.12.7.2. Channel Strategies
  • 21.3.13. Sino Biopharma
    • 21.3.13.1. Overview
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Sales Footprint
    • 21.3.13.4. Key Financial
    • 21.3.13.5. Key Developments
    • 21.3.13.6. SWOT Analysis
    • 21.3.13.7. Strategy Overview
      • 21.3.13.7.1. Marketing Strategies
      • 21.3.13.7.2. Channel Strategies
  • 21.3.14. HUTCHMED
    • 21.3.14.1. Overview
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Sales Footprint
    • 21.3.14.4. Key Financial
    • 21.3.14.5. Key Developments
    • 21.3.14.6. SWOT Analysis
    • 21.3.14.7. Strategy Overview
      • 21.3.14.7.1. Marketing Strategies
      • 21.3.14.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology

관련자료